Preventing Coronary Artery Lesions in Kawasaki Disease

Overview

Journal Biomed J

Publisher Elsevier

Specialty General Medicine

Date 2017 Jun 28

PMID 28651735

Citations 33

Authors

Ho-Chang Kuo

Affiliations

Soon will be listed here.

Abstract

A form of systemic vasculitis that affects mostly small and medium-sized vessels, Kawasaki disease (KD) is most commonly found in children under the age of 5 years old. Though its etiology is unknown, KD has been the most frequent acquired heart disease in developing countries. Its incidence has increased over recent decades in many centuries, including Japan, Korea, and China. The most severe complications of KD are coronary artery lesions (CAL), including dilation, fistula, aneurysm, arterial remodeling, stenosis, and occlusion. Aneurysm formation has been observed in 20-25% of KD patients that do not receive intravenous immunoglobulin (IVIG) treatment, and in 3-5% that do receive it. Coronary artery dilation has been found in about 30% of KD patients in the acute stage, although mostly in the transient form. Diminishing the occurrence and regression of CAL is a vital part of treating KD. In this review article, I demonstrate the clinical method to prevent CAL formation used at the Kawasaki Disease Center in Taiwan.

Citing Articles

Whole-exome sequencing reveals Kawasaki disease susceptibility genes and their association with coronary artery lesion.

Wang Y, Chen X, Zhang D, Chen R, Alifu A Front Pediatr. 2024; 12:1400123.

PMID: 39318622 PMC: 11420030. DOI: 10.3389/fped.2024.1400123.

Research perspective in the clinical management of Kawasaki disease.

Yi X, Zhang W, Wang D, Wang X, Zhang F Front Pediatr. 2024; 12:1415941.

PMID: 39044731 PMC: 11263076. DOI: 10.3389/fped.2024.1415941.

Etiology and prognosis of non-Kawasaki disease induced coronary aneurysms in children: a retrospective case series study.

Lin Y, Qi H, Liu Y, Wu H, Li Y, Shi L Eur J Pediatr. 2024; 183(10):4229-4234.

PMID: 38990385 PMC: 11413059. DOI: 10.1007/s00431-024-05666-5.

Knowledge framework of intravenous immunoglobulin resistance in the field of Kawasaki disease: A bibliometric analysis (1997-2023).

Zhang J, Huang H, Xu L, Wang S, Gao Y, Zhuo W Immun Inflamm Dis. 2024; 12(5):e1277.

PMID: 38775687 PMC: 11110715. DOI: 10.1002/iid3.1277.

Clinical indicators combined with S100A12/TLR2 signaling molecules to establish a new scoring model for coronary artery lesions in Kawasaki disease.

Wu Y, Wang S, Zhou Y, Yang Y, Li S, Yin W PLoS One. 2023; 18(10):e0292653.

PMID: 37824465 PMC: 10569519. DOI: 10.1371/journal.pone.0292653.

References

Uehara R, Igarashi H, Yashiro M, Nakamura Y, Yanagawa H . Kawasaki disease patients with redness or crust formation at the Bacille Calmette-Guérin inoculation site. Pediatr Infect Dis J. 2009; 29(5):430-3. DOI: 10.1097/INF.0b013e3181cacede. View

Nakamura Y, Yashiro M, Uehara R, Sadakane A, Tsuboi S, Aoyama Y . Epidemiologic features of Kawasaki disease in Japan: results of the 2009-2010 nationwide survey. J Epidemiol. 2012; 22(3):216-21. PMC: 3798622. DOI: 10.2188/jea.je20110126. View

Onouchi Y, Ozaki K, Burns J, Shimizu C, Terai M, Hamada H . A genome-wide association study identifies three new risk loci for Kawasaki disease. Nat Genet. 2012; 44(5):517-21. DOI: 10.1038/ng.2220. View

Tseng H, Ho J, Guo M, Lo M, Hsieh K, Tsai W . Bull's eye dermatoscopy pattern at bacillus Calmette-Guérin inoculation site correlates with systemic involvements in patients with Kawasaki disease. J Dermatol. 2016; 43(9):1044-50. DOI: 10.1111/1346-8138.13315. View

Khor C, Davila S, Breunis W, Lee Y, Shimizu C, Wright V . Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease. Nat Genet. 2011; 43(12):1241-6. DOI: 10.1038/ng.981. View

Newburger J, Sleeper L, McCrindle B, Minich L, Gersony W, Vetter V . Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med. 2007; 356(7):663-75. DOI: 10.1056/NEJMoa061235. View

Wang C, Wu Y, Liu C, Kuo H, Yang K . Kawasaki disease: infection, immunity and genetics. Pediatr Infect Dis J. 2005; 24(11):998-1004. DOI: 10.1097/01.inf.0000183786.70519.fa. View

Kuo H, Yang K, Chang W, Ger L, Hsieh K . Kawasaki disease: an update on diagnosis and treatment. Pediatr Neonatol. 2012; 53(1):4-11. DOI: 10.1016/j.pedneo.2011.11.003. View

Onouchi Y, Gunji T, Burns J, Shimizu C, Newburger J, Yashiro M . ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat Genet. 2007; 40(1):35-42. PMC: 2876982. DOI: 10.1038/ng.2007.59. View

10.

Guo M, Tseng W, Ko C, Pan H, Hsieh K, Kuo H . Th17- and Treg-related cytokine and mRNA expression are associated with acute and resolving Kawasaki disease. Allergy. 2015; 70(3):310-8. DOI: 10.1111/all.12558. View

11.

Ahn S, Kim D . Treatment of intravenous immunoglobulin-resistant Kawasaki disease with methotrexate. Scand J Rheumatol. 2005; 34(2):136-9. DOI: 10.1080/03009740510026328. View

12.

Wu T, Chao C, Lin S, Chen J . Low-dose dextromethorphan, a NADPH oxidase inhibitor, reduces blood pressure and enhances vascular protection in experimental hypertension. PLoS One. 2012; 7(9):e46067. PMC: 3457948. DOI: 10.1371/journal.pone.0046067. View

13.

. Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2008)--digest version. Circ J. 2010; 74(9):1989-2020. DOI: 10.1253/circj.cj-10-74-0903. View

14.

Nakamura Y, Yashiro M, Uehara R, Oki I, Watanabe M, Yanagawa H . Epidemiologic features of Kawasaki disease in Japan: results from the nationwide survey in 2005-2006. J Epidemiol. 2008; 18(4):167-72. PMC: 4771586. DOI: 10.2188/jea.je2008001. View

15.

Sudo D, Nakamura Y . Nationwide surveys show that the incidence of recurrent Kawasaki disease in Japan has hardly changed over the last 30 years. Acta Paediatr. 2017; 106(5):796-800. DOI: 10.1111/apa.13773. View

16.

Hsieh K, Weng K, Lin C, Huang T, Lee C, Huang S . Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited. Pediatrics. 2004; 114(6):e689-93. DOI: 10.1542/peds.2004-1037. View

17.

Kuo H, Chao M, Hsu Y, Lin Y, Huang Y, Yu H . CD40 Gene polymorphisms associated with susceptibility and coronary artery lesions of Kawasaki disease in the Taiwanese population. ScientificWorldJournal. 2012; 2012:520865. PMC: 3354684. DOI: 10.1100/2012/520865. View

18.

Kuo H, Yang K, Juo S, Liang C, Chen W, Wang Y . ITPKC single nucleotide polymorphism associated with the Kawasaki disease in a Taiwanese population. PLoS One. 2011; 6(4):e17370. PMC: 3077380. DOI: 10.1371/journal.pone.0017370. View

19.

Newburger J, Takahashi M, Burns J, Beiser A, Chung K, Duffy C . The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986; 315(6):341-7. DOI: 10.1056/NEJM198608073150601. View

20.

Huang W, Huang L, Chang I, Chang L, Chiang B, Chen P . Epidemiologic features of Kawasaki disease in Taiwan, 2003-2006. Pediatrics. 2009; 123(3):e401-5. DOI: 10.1542/peds.2008-2187. View